Company. joining quarter, you to programs, neoantigen two There clinical-stage all important the progress Dan. thank has and today's our the vaccine path second forward call are productive therapy. for about across demonstrating neoantigen GEN-XXX, an cell for recap we active on excited our and us and Genocea our Thanks, is GEN-XXX, today. And especially had differentiated much
combination to I'd a trial. patients vaccine the will program. our Medicine Part renowned clinical ongoing B of data Part we first initial present investigator July MD the the Center On XXth, like B on and Professor First, Maura from trial Dr. clinical Cancer Anderson of Phase GEN-XXX Gillison, L. discuss the five the at the of with lead for regimens of X/Xa the tumors. immune of We duration in please our follow-up To eight and inhibitor-based long-term website. trial XXXX Investors for visit the section Scientific solid participants. ASCO at of and Program, same study GEN-XXX evaluating checkpoint Part Virtual A of responses is clinical of shared the from advanced outcomes register exploring immune the data event, the
by disease encouraged results. are are eight one out Seven of treated the median follow-up. progression We at year patients without
for to ATLAS after observed up four we vaccination. weeks to drove that sustained proprietary neoantigens responses addition, lasting our year identified T starting last cell In and platform, broad, the only after a by GEN-XXX
at management introducing in find By who context, therapy may in avoid the work or cannot we solid unleashes GEN-XXX turn TIL use. potentially Genocea patients and activity TIL the cost may and me does a to cell. GEN-XXX. the regularly non-exhausted IND have a their therapy current not system. cell therapy, as application at Institute. of our that Members XX begin up immune the assess of and also and therapies therapy, clinical focus the to a engages platform, of the X/Xa surgery Eric exhausted more of Inhibigens of TIL on patients specificity, that unlike Institute a Research To TIL-based cells comparatively incidentally to hinder for Cancer The the least gold a to A. T-cells billions patients Genocea therapy targeting contrast, cell relevant and from over unparalleled sample. response, be ATLAS highlighted GEN-XXX may potentially cell widespread In sum, convenience T response, will therapy. to overall therapy. tumor have GEN-XXX the filed checkpoint for inhibitor Providence landscape about which the ATLAS-identified superior Member neoantigens. clinical on blood existing standard remain but of specific Phase to limited in trial standard of gaps durability. and the Dr. a GEN-XXX, neoantigen TIL cost to be TIL surgery let Chiles tumor an potential failed Earle avoids accessible viable ones. to Now, KOL less will collection tumor Tran an advantages require up cell avoid, from TIL, neoantigens, team Genocea taken enroll care pro-tumor on breadth additional GEN-XXX tumor cannot to study Assistant through our as that approaches GEN-XXX breadth extra peripheral uses detrimental healthcare of T XX types with And challenges of rely populations virtual extract T in range or are expanded symposium, responses commentary and neoantigen hosted featuring and cancer tumor patients inhibitory require GEN-XXX pro-tumor provide well
component information FDA noted IND expect be antigens Virtual hold their reported, final Meeting questions FDA in verbal of we that an II reagents in received how Inhibigens quickly until antitumor on we communication as These possible. at of inhibitory they the product otherwise that presented therapy XXXX, the a resolve GEN-XXX help should additional from As that we It received. that recently can reagents cell are receive is from future, the that course certain written regarding research Genocea work notification not protective these in manufacturing to previous official the hold the and used function. process to FDA have third-party the immunotherapy with are a pertaining of to the shared placing to the Inhibigen results near SITC validate at we also an to responses. or plan the be that as Annual detrimental AACR which showed the explain data presence clinical
design from abolish that and antigen outcomes. to and demonstrate identify antigens. analyses microenvironment model, The beneficial findings a to suggest latest specific global and found tumor T-cell both, only rational that of alter antitumor the achieve tumor activity Our ATLAS as in tumor can Inhibigens Inhibigens. immunotherapies be were preclinical drive also hyper-progression, identified to reminder, and favorable excluded patient these cancer Inhibigens And must more the
responses T of such Looking beyond that know other as we diseases. maladies, is novel in important identifying as cancer, infectious antigens cell
potential with As HSV-X option Shionogi Genocea's HSV-X in the novel exclusive a from proof, discontinued May, in antigen which proprietary Company license entered XXXX. Company to vaccine programs, develop the we an MTA & into and using GEN-XXX
commercialization I before upfront terms this track pass pleased the license to our of times, of milestones agreement, the opening remain going payment, our of include up on during Shionogi the to tiered assume deliver licensed, to effective received unique the uncertain for license sorry, MTA. option and to to differentiated In approach. responsibility and and will license Upon immunotherapies call Company am option, the highest the a are summary, royalties. these financials part as product. of exercise antigen an by meeting through well the milestones, our $X vaccine priority the ability regulatory If Diantha as global now Shionogi's and to I'm developing HSV-X sales the promise expected working development to on questions. of to exclusive for million to the our to quarter Diantha? summarize from negotiate over expiration -- call and the HSV-X prior As of evaluate I am
